DCPIB (SN-401) is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC), inhibits TRESK, TASK1 and TASK3 with IC50 of 0.14, 0.95, and 50.72 uM respectively.
DCPIB (SN-401) is a SWELL1 channel inhibitor that bind the SWELL1-LRRC8 channel complexes (IC50=3.9 uM).
SN-401 increases adipocyte SWELL1 protein expression, and SWELL1-dependent insulin signaling.
SN-401 increases SWELL1 and improves systemic glucose homeostasis in murine T2D models by enhancing insulin sensitivity and secretion.
SN-401 improves systemic insulin sensitivity, tissue glucose uptake, and nonalcoholic fatty liver disease in murine T2D models.
SN-401 inhibits ICl,SWELL but promote SWELL1-dependent signaling at sub-micromolar concentrations (0.1-1 uM).
SN-401 prevents reductions in SWELL1 protein and rescues SWELL1-dependent islet insulin secretion under glucolipotoxic conditions.
SN-401 congeners improve glycemic control in murine T2D models